These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21083238)

  • 1. Overview of metabolite safety testing from an industry perspective.
    Anderson S; Knadler MP; Luffer-Atlas D
    Bioanalysis; 2010 Jul; 2(7):1249-61. PubMed ID: 21083238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
    Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
    Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.
    Caceres-Cortes J; Reily MD
    Bioanalysis; 2010 Jul; 2(7):1263-76. PubMed ID: 21083239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.
    Nedderman AN; Wright P
    Bioanalysis; 2010 Jul; 2(7):1235-48. PubMed ID: 21083237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed Matrix Method Provides A Reliable Metabolite Exposure Comparison for Assessment of Metabolites in Safety Testing (MIST).
    Takahashi RH; Khojasteh C; Wright M; Hop CECA; Ma S
    Drug Metab Lett; 2017 Nov; 11(1):21-28. PubMed ID: 28699487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.
    Nedderman AN; Dear GJ; North S; Obach RS; Higton D
    Xenobiotica; 2011 Aug; 41(8):605-22. PubMed ID: 21446837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA; Obach RS
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decade of drug metabolite safety testing: industry and regulatory shared learning.
    Luffer-Atlas D; Atrakchi A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):897-900. PubMed ID: 28797172
    [No Abstract]   [Full Text] [Related]  

  • 12. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
    Espina R; Yu L; Wang J; Tong Z; Vashishtha S; Talaat R; Scatina J; Mutlib A
    Chem Res Toxicol; 2009 Feb; 22(2):299-310. PubMed ID: 18980340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing MIST (Metabolites in Safety Testing): bioanalytical approaches to address metabolite exposures in humans and animals.
    Gao H; Obach RS
    Curr Drug Metab; 2011 Jul; 12(6):578-86. PubMed ID: 21434861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance.
    Yu H; Bischoff D; Tweedie D
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1539-49. PubMed ID: 21067462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum.
    Timmerman P; Blech S; White S; Green M; Delatour C; McDougall S; Mannens G; Smeraglia J; Williams S; Young G
    Bioanalysis; 2016 Jun; 8(12):1297-305. PubMed ID: 27217058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel MS solutions inspired by MIST.
    Ramanathan R; Josephs JL; Jemal M; Arnold M; Humphreys WG
    Bioanalysis; 2010 Jul; 2(7):1291-313. PubMed ID: 21083241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.